Table 3.
Comparison of the outcomes among the three groups after 12 weeks of treatment.
| MET group (n = 54) | SPI group (n = 53) | COM group (n = 51) | |
|---|---|---|---|
| Number of menstruation per year (normal ≥8/year) | 5.9 ± 2.1 | 6.9 ± 2.4 | 6.1 ± 2.3 |
| SBP (mm Hg) | 112 ± 11 | 123 ± 11 | 117 ± 8 |
| DBP (mm Hg) | 72 ± 12 | 78 ± 8 | 74 ± 7 |
| Weight (kg) | 61.8 ± 11.6 | 63.7 ± 16.2 | 54.6 ± 8.8 |
| BMI (kg/m2) | 25.0 ± 4.2 | 25.2 ± 6.5 | 24.7 ± 3.6 |
| WHR | 0.83 ± 0.04 | 0.82 ± 0.07 | 0.81 ± 0.10 |
| LH/FSH | 1.40 ± 0.90 | 1.59 ± 0.81 | 1.92 ± 0.99 |
| TC (mmol/L) | 4.46 ± 0.68 | 4.75 ± 0.98 | 4.64 ± 0.71 |
| TT (nmol/L) | 2.05 ± 0.89 | 1.79 ± 0.69 | 1.88 ± 0.60ab |
| FAI | 5.78 ± 7.62 | 4.88 ± 4.2 | 3.58 ± 3.0ab |
| QUICKI | 0.36 ± 0.03 | 0.34 ± 0.02 | 0.36 ± 0.03 |
| HOMA-IR | 1.92 ± 1.07 | 2.38 ± 1.14 | 1.71 ± 0.91ab |
| HOMA-β | 1978.0 ± 7068 | 867.76 ± 651 | 973.7 ± 1264b |
| FBG (mmol/L) | 4.65 ± 0.45 | 5.02 ± 0.58 | 4.68 ± 0.58b |
| FINS (mU/L) | 9.14 ± 4.81 | 10.62 ± 4.77 | 8.15 ± 3.92 |
| mF-G score | 3.9 ± 1.3 | 4.1 ± 1.5 | 4.0 ± 1.2 |
| AUCins | 273.3 ± 131 | 271.2 ± 143.2 | 232.1 ± 121.3ab |
| AUCglu | 20.6 ± 4.3 | 19.2 ± 4.6 | 17.5 ± 4.2 |
| Rosenfield score | 0.84 ± 0.98 | 0.88 ± 0.90 | 0.83 ± 1.00 |
a P < 0.05 vs. metformin. bP < 0.05 vs. spironolactone. MET: metformin; SPI: spironolactone; COM: combined; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-hip ratio; LH/FSH: luteinizing hormone/follicular-stimulating hormone; TC: total cholesterol; TT: total testosterone; FAI: free androgen index; QUICKI: quantitative insulin sensitivity check index; HOMA: homeostatic model assessment; IR: insulin resistance; FPG: fasting plasma glucose; FINS: fasting insulin; mG-G score: modified Ferriman–Gallwey score; AUCglu: oral glucose tolerance test area under curve-glucose; AUCins: oral glucose tolerance test area under curve-insulin.